Benign Prostatic Hyperplasia Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Nymox Pharma, AiViva, Abbott, Pfizer, Dongkook, Urovant

Benign Prostatic Hyperplasia Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) -  DelveInsight | Key Companies - Nymox Pharma, AiViva, Abbott, Pfizer, Dongkook, Urovant
Delveinsight Business Research LLP
The Benign Prostatic Hyperplasia Market is anticipated to evolve immensely in the coming years owing to the increase in the cases of risk factors such as obesity, heart, and circulatory disease, type 2 diabetes, a rise in the geriatric population along with the expected approval of emerging therapies such as Vibegron (Urovant Sciences, DKF-313 (Dongkook Pharmaceutical). The pipeline for Benign Prostatic Hyperplasia brings a positive ray of hope for a better treatment pattern in the market

Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. Key players, such as Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, etc., are developing therapies for the treatment of Benign Prostatic Hyperplasia.

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Benign Prostatic Hyperplasia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Benign Prostatic Hyperplasia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Benign Prostatic Hyperplasia Market

Benign Prostatic Hyperplasia: An Overview

Benign prostatic hyperplasia—also called Benign Prostatic Hyperplasia —is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention—the inability to empty the bladder completely—cause many of the problems associated with benign prostatic hyperplasia.

The cause of benign prostatic hyperplasia is not well understood; however, it occurs mainly in older men. Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty. For this reason, some researchers believe factors related to aging and the testicles may cause benign prostatic hyperplasia. Scientific studies have suggested that benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth.

Benign Prostatic Hyperplasia Market Key Facts 

  • As per a study conducted by Lim et al. (2017), the histological prevalence of Benign Prostatic Hyperplasia was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively.

  • Similarly, Lee et al. (2017), based on more than seven International Prostate Symptom Scores (I-PSS), determined the prevalence of Benign Prostatic Hyperplasia in Germany from the study by Berges et al. (2001) as 29.3%.

  • As per an article by Boyle et al. (n.d.), half of the men over 60 may have symptoms compatible with Benign Prostatic Hyperplasia, and up to 60% of men over 60 may have hypertension. Even if they are unrelated etiologically and occur independently, this means at least one-eighth of all men over age 60 acquire both symptomatic Benign Prostatic Hyperplasia and Hypertension.

  • As per the article by Nash et al. (2010), general practitioners in the UK will, on average, have 50 men on their list between the ages of 60‒80 years who have moderate or severe urinary symptoms related to Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Benign Prostatic Hyperplasia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Benign Prostatic Hyperplasia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Benign Prostatic Hyperplasia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Benign Prostatic Hyperplasia Epidemiology, Segmented as –

  • Total Prevalent Cases of Benign Prostatic Hyperplasia in the 7MM [2019–2032]

  • Age-specific Prevalent Cases of Benign Prostatic Hyperplasia in the 7MM [2019–2032]

  • Diagnosed and Treatable Cases of Benign Prostatic Hyperplasia in the 7MM [2019–2032]

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to be launched during the study period. The analysis covers the Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Benign Prostatic Hyperplasia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Benign Prostatic Hyperplasia Market Will Evolve and Grow by 2032 @

Benign Prostatic Hyperplasia Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Benign Prostatic Hyperplasia. Currently, Nymox Pharmaceutical is leading the therapeutics market with its Benign Prostatic Hyperplasia drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Benign Prostatic Hyperplasia Therapeutics Market Include:

  • Nymox Pharmaceutical

  • ASKA Pharmaceutical

  • Otsuka Pharmaceutical

  • Aviva BioPharma

  • Veru Healthcare

  • Boryung Pharmaceutical

  • KAEL-GemVax

  • Dong-A ST/Mezzion

And Many Others

Benign Prostatic Hyperplasia Therapies Covered in the Report Include:

  • Fexapotide: Nymox Pharmaceutical

  • AIV007: AiViva BioPharma

  • Hytrin (terazosin hydrochloride): Abbott Laboratories

  • Cardura (doxazosin mesylate): Pfizer

  • DKF-313: Dongkook Pharmaceutical

  • Vibegron: Urovant Sciences

  • AUS-131 (S-equo): Ausio Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Benign Prostatic Hyperplasia Competitive Intelligence Analysis

4. Benign Prostatic Hyperplasia Market Overview at a Glance

5. Benign Prostatic Hyperplasia Disease Background and Overview

6. Benign Prostatic Hyperplasia Patient Journey

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Benign Prostatic Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices

9. Benign Prostatic Hyperplasia Unmet Needs

10. Key Endpoints of Benign Prostatic Hyperplasia Treatment

11. Benign Prostatic Hyperplasia Marketed Products

12. Benign Prostatic Hyperplasia Emerging Drugs and Latest Therapeutic Advances

13. Benign Prostatic Hyperplasia Seven Major Market Analysis

14. Attribute Analysis

15. Benign Prostatic Hyperplasia Market Outlook (In US, EU5, and Japan)

16. Benign Prostatic Hyperplasia Access and Reimbursement Overview

17. KOL Views on the Benign Prostatic Hyperplasia Market

18. Benign Prostatic Hyperplasia Market Drivers

19. Benign Prostatic Hyperplasia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States